Novo Faces Narrowed Investor Suit Over Obesity Drug Claims
A New Jersey federal judge narrowed a proposed securities class action against Novo Nordisk, preserving claims that it misled investors about the CagriSema obesity drug's tolerability and a flexible protocol used...To view the full article, register now.
Already a subscriber? Click here to view full article